The term plasma medicine was created only two decades ago, and research in this field has grown tremendously in recent years. Great advances have been made in understanding the mechanisms involved in the interaction between cold atmospheric plasma and living cells and tissues. Numerous research groups, especially in Europe, the United States and Asia, try to achieve a deeper understanding of these mechanisms. Results of numerous in vitro, ex vivo and in vivo experiments have been published showing the excellent properties of this treatment. The arrival of this technology in our reference hospitals is getting closer.
In recent years, efforts have multiplied in this field and knowledge of the applications of plasma treatment has grown enormously. In 2008 the Food and Drug Administration (FDA) approved the use of cold atmospheric plasma in dermatological applications and in 2010 the first clinical trial for wound treatment was carried out in Germany, which resulted in the approval of the treatment in 2013.
Cold atmospheric plasma treatment has been shown to accelerate healing without causing necrosis, reduce the bacterial load in wounds (including those colonized by antibiotic-resistant bacteria), and promote angiogenesis. The use of plasma in venous ulcers is especially convenient since these, on many occasions, remain open for long periods of time.
The main mechanism of action underlying the therapeutic effect of cold atmospheric air plasmas is the effect of the electric fields produced by the charged particles that make up the plasma. These fields are imperceptible by the patient; however, the effect on the microcirculation in the application area of the wound is very noticeable. The improvement in microcirculation lasts longer than the treatment period, as shown by the reported oxygen saturation studies using DBD (Dielectric Barrier Discharge) cold air plasmas, including clinical trials. Improved capillary blood flow increases local oxygen saturation and nutrient supply, thus promoting wound healing.
MEDICAL PLASMAS maintains an active collaboration with the Clinic University of Navarra where a compassionate use treatment has been carried out with significant success and a clinical trial is being prepared to obtain the medical CE marking of the PlasmAction Med team. The Clinic University of Navarra is a pioneer in the development of clinical trials and the implementation of cutting-edge medical technologies..
Send us your questions
an expert will contact you asap